Expert Opinion on Pharmacotherapy·16 SepInvestigating oral blarcamesine for treatment of early Alzheimer's diseaseReviewInterventionsPaper
Translational Psychiatry·16 SepRegional juxtacortical microstructural changes and gene expression provide insights into neurodegeneration in Alzheimer's diseaseStudy in peopleMechanismsPaper
Drugs·1 SepPlasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging OutcomesTrial in peopleInterventionsPaper
Alzheimer's & Dementia·7 AugManagement of multimorbidity in the midst of cognitive decline through clinical decision-support softwareCross-sectional study of 17,915 peoplePopulationsPaper
AAIC 2025 Abstract·26 DecPrecision Medicine in Alzheimer’s Disease (AD): Observed Efficacy Treatment Effects from Blarcamesine Clinical AD TrialsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecA Patient‐Centric, Digital Multimodal Post‐Market Approval Continuous Monitoring of Drug Safety & Efficacy Platform for BlarcamesineAI & dataPaper
AAIC 2025 Abstract·26 DecPhase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease PatientsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·25 DecExternally‐Led Patient‐Focused Drug Development Meeting (EL‐PFDD) for Dementia with Lewy Bodies—DLB: Voices of Lived Experience on Life with Lewy and Unmet Treatment NeedsIndustry & policyPaper
AAIC 2025 Abstract·25 DecPhotobiomodulation: A Promising Safe Therapy for Alzheimer's DiseaseReviewInterventionsPaper
AAIC 2025 Abstract·23 DecCorrelations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 HomozygotesTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecEfficacy and Safety of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Topline Results from the APOLLOE4 Phase 3 TrialTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecValiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78‐Week APOLLOE4 Phase 3 TrialTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecSafety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early ADTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecBlood‐Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer’s Disease in the United StatesStudy in peopleBiomarkersPaper
AAIC 2025 Abstract·23 DecReal‐World Insights on the Lecanemab Patient Pathway in Early Alzheimer’s Disease in the United StatesStudy in peoplePopulationsPaper
AAIC 2025 Abstract·23 DecReal‐World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic TherapyStudy in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecReal‐World Use of Lecanemab With Consideration of Race, Ethnicity, and Geographical DiversityStudy in peoplePopulationsPaper
AAIC 2025 Abstract·23 DecReal‐World Use of Lecanemab in Patients With Early Alzheimer’s Disease in the United States: a Case Series ReviewStudy in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecSpectris™ treatment is associated with significant time saved in the OVERTURE feasibility and open label extension (OLE) studyTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecIndirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported ResultsComputational studyInterventionsPaper